Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045275 | 1.00 | PTAFR (0.48) | PTAFRKDM4EFYNEGLN1KMT2A | |
| SCHEMBL29411462 | 0.91 | KDM4E (0.49) | PTAFRKDM4EFYNKMT2AROCK2 | |
| SCHEMBL21045432 | 0.91 | KDM4E (0.49) | PTAFRKDM4EFYNKMT2AROCK2 | |
| SCHEMBL21045159 | 0.86 | PTAFR (0.53) | PTAFRKDM4E | |
| SCHEMBL29411435 | 0.86 | PTAFR (0.53) | PTAFRKDM4E | |
| SCHEMBL21045131 | 0.85 | PTAFR (0.54) | PTAFRKDM4EEGLN1KMT2AROCK2 | |
| SCHEMBL29411534 | 0.85 | PTAFR (0.54) | PTAFRKDM4EEGLN1KMT2AROCK2 | |
| SCHEMBL29411540 | 0.81 | ADORA2A (0.43) | KDM4EFYNCNR1 | |
| SCHEMBL21045509 | 0.81 | ADORA2A (0.43) | KDM4EFYNCNR1 | |
| SCHEMBL21045340 | 0.79 | PTAFR (0.59) | PTAFRKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188035-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE LLC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12247010-B2 | Tubulin inhibitors | LIN BIOSCIENCE INC. (TW) | 2025-03-11 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PTAFR 2124/4885KDM4E 4032/4885FYN 2141/4885 |
| US-12247010-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | PTAFR 2124/4885KDM4E 4032/4885FYN 2141/4885 |
| US-20250188035-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | PTAFR 2124/4885KDM4E 4032/4885FYN 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.